Patents Examined by D Margaret M Seaman
  • Patent number: 10155746
    Abstract: A medicament or pharmaceutical composition for the treatment of respiratory syncytial virus, which is a compound having the following formula: or a pharmaceutically acceptable salt thereof. A method of treating respiratory syncytial virus includes administering to a patient an effective amount of the compound or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 18, 2018
    Assignee: OBSCHESTVO S OGRANICHENNOT OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova
  • Patent number: 10155747
    Abstract: A method for preparing a compound of formula I: or a pharmaceutically acceptable salt thereof, by heating of dicarboxylic acid monoamide of formula II with a dehydrating agent in an organic solvent.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: December 18, 2018
    Assignee: OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU “PHARMENTERPRISES”
    Inventors: Vladimir Evgenievich Nebolsin, Tatyana Alexandrovna Kromova
  • Patent number: 10144724
    Abstract: Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I): or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: December 4, 2018
    Assignee: Araxes Pharma LLC
    Inventors: Liansheng Li, Jun Feng, Yun Oliver Long, Yuan Liu, Tao Wu, Pingda Ren, Yi Liu
  • Patent number: 10144747
    Abstract: Described herein are perfluoroalkylated zinc compounds having the structure of Formula (I) or Formula (II), which can be used to perfluoroalkylate organic, inorganic and organometallic substrates. Methods of making and using these compounds by reacting zinc or a dialkylzinc compound with a perfluoroalkyl dihalide in a solvent such as tetrahydrofuran, dioxane or diglyme, are also described.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: December 4, 2018
    Inventor: David Vicic
  • Patent number: 10144712
    Abstract: The present invention discloses novel N-Heterocyclic compounds of formula A, [Formula A] And a ligand-enabled palladium-catalyzed process for preparation of novel N-Heterocyclic compounds of Formula A via C—H alkynylation of N-heterocycles with alkynyl halides.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: December 4, 2018
    Assignee: Council of Scientific and Industrial Research
    Inventors: Balaraman Ekambaram, Vinod Gokulkrishna Landge
  • Patent number: 10131634
    Abstract: The instant application discloses methods of treating, reducing, or preventing pain in a mammal, which may include administering a compound capable of modulating a transient receptor potential channel. In one aspect, the TRP channel may be TRPC4. Types of pain contemplated by the present disclosure include acute, chronic, neuropathic, and nociceptive pain.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: November 20, 2018
    Assignee: Poseida Therapeutics, Inc.
    Inventors: Eric M. Ostertag, John Stuart Crawford
  • Patent number: 10125117
    Abstract: Disclosed herein is an in vitro or in vivo method of activating or reversing inactivation of acetylcholinesterase (AChE) or butyrylcholinesterase (BuchE) using compounds of the present disclosure. Also disclosed is a method of treating a subject exposed to a nerve agent using such compounds. Also disclosed is a method of treating organophosphate poisoning in a subject using such compounds. Also disclosed is a method of modulating neuronal signaling and transmission in a subject using such compounds.
    Type: Grant
    Filed: July 15, 2015
    Date of Patent: November 13, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Milan Stojanovic, Francine Katz, Donald W. Landry
  • Patent number: 10125152
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 13, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Patent number: 10118060
    Abstract: A Schiff base compound configured to detoxify a toxic chemical agent. The toxic chemical agent includes at least one leaving group and the Schiff base compound includes an imine having at least one Lewis base and an alkyl substituent or an aryl substituent having an electron acceptor. The at least one Schiff base nitrogen is spaced way from the electron acceptor by a distance that ranges from about 200 pm to about 1000 pm.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: November 6, 2018
    Assignee: The United States of America as represented by the Secretary of the Air Force
    Inventors: Jeffery Ray Owens, Wallace Bruce Salter, Katherine Moss Simpson
  • Patent number: 10112901
    Abstract: Disclosed are a method for preparing a dabigatran etexilate intermediate, and an intermediate compound. The method for preparing a dabigatran etexilate intermediate 4 comprises: reacting a compound 3 with a C1-C3 alkyl alcohol solution of methylamine in an organic solvent, wherein, X=chlorine, bromine, or iodine. Also disclosed are an intermediate compound 3 and a preparation method thereof. The method for preparing a dabigatran etexilate intermediate of the present invention has the advantages of simple process, easy operation, high yield, and easy purification, thus being suitable for industrial production.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 30, 2018
    Assignees: SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHINA STATE INSTITUTE OF PHARMACEUTICAL INDUSTRY, CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Yajun Guo, Hanbin Shan, Xueyan Zhu, Zhedong Yuan, Xiong Yu, Meng Guo, Mingtong Hu, Duzheng Wang, Yu Huang
  • Patent number: 10112905
    Abstract: Aminoquinoline compounds useful for treating chronic pain, addiction, and other conditions are provided. The aminoquinoline compound is represented by Formula (I) which is defined in the specification.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: October 30, 2018
    Assignee: LOHOCLA RESEARCH CORPORATION
    Inventor: Boris Tabakoff
  • Patent number: 10106546
    Abstract: Compounds that modulate the oxidoreductase enzyme indoleamine 2,3-dioxygenase, and compositions containing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by indoleamine 2,3-dioxygenase is also provided.
    Type: Grant
    Filed: March 27, 2017
    Date of Patent: October 23, 2018
    Assignee: Flexus Biosciences, Inc.
    Inventors: Hilary Plake Beck, Juan Carlos Jaen, Maksim Osipov, Jay Patrick Powers, Maureen Kay Reilly, Hunter Paul Shunatona, James Ross Walker, Mikhail Zibinsky, James Aaron Balog, David K. Williams, Jay A. Markwalder, Emily Charlotte Cherney, Weifang Shan, Audris Huang
  • Patent number: 10106522
    Abstract: The invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, a method of synthesis of said compounds, pharmaceutical compositions comprising them and their use in the treatment and/or prevention of conditions mediated by H1 histamine receptor, such as allergic disorders or diseases.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: October 23, 2018
    Assignee: Faes Farma, S.A.
    Inventors: Rosa Rodes Solanes, Roberto Olivera Tizne, Gonzalo Hernández Herrero, Víctor Rubio Royo, Francisco Ledo Gómez
  • Patent number: 10105359
    Abstract: The present invention relates to tetrahydroisoquinoline derivatives according to formula (I), which are Positive Allosteric Modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: October 23, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Anne Valade, Eric Jnoff, Ali Ates, Pierre Burssens, David Skolc, Zara Sands, Benoit Mathieu
  • Patent number: 10100034
    Abstract: The present invention relates a new process to synthesize 1-((4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)methyl)cyclopropanamine (AL3818). A stable crystalline form of A13818 has been prepared. Salts and their crystalline forms of AL3818 have been also prepared. Anti-cancer and optometric activities of AL3818 and its salts have been further tested. New process has been outlined in Scheme I.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: October 16, 2018
    Assignee: Advenchen Pharmaceuticals, LLC
    Inventors: Guoqing Paul Chen, Changren Yan
  • Patent number: 10098949
    Abstract: Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: October 16, 2018
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Manmohan Singh, David A. G. Skibinksi, Tom Yao-Hsiang Wu, Yongkai Li, Alex Cortez, Xiaoyue Zhang, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan, Kathy Yue
  • Patent number: 10093685
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 9, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Patent number: 10087143
    Abstract: The invention relates to pyridone amide compounds of formula I and I? or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: October 2, 2018
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Sara Sabina Hadida-Ruah, Corey Anderson, Vijayalaksmi Arumugam, Iuliana Luci Asgian, Brian Richard Bear, Andreas P. Termin, James Philip Johnson
  • Patent number: 10077228
    Abstract: The invention relates to a compound of formula (I) where R1, R2, R3, R4 are each independently selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, —(C3-C20)-heteroaryl; at least one of the R1, R2, R3, R4 radicals is a —(C6-C20)-heteroaryl radical having at least six ring atoms; and R1, R2, R3, R4, if they are —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —(C6-C20)-aryl, —(C3-C20)-heteroaryl or —(C6-C20)-heteroaryl, may each independently be substituted by one or more substituents selected from —(C1-C12)-alkyl, —(C3-C12)-cycloalkyl, —(C3-C12)-heterocycloalkyl, —O—(C1-C12)-alkyl, —O—(C1-C12)-alkyl-(C6-C20)-aryl, —O—(C3-C12)-cycloalkyl, —S—(C1-C12)-alkyl, —S—(C3-C12)-cycloalkyl, —COO—(C1-C12)-alkyl, —COO—(C3-C12)-cycloalkyl, —CONH—(C1-C12)-alkyl, —CONH—(C3-C12)-cycloalkyl, —CO—(C1-C12)-alkyl, —CO—(C3-C12)-cycloalkyl, —N—[(C1-C12)-alkyl]2, —(C6-C20)-aryl, —(C6-C20)-aryl-(C1-C12)-alkyl, —(C6-C20)-aryl-O—(C1-C12)-alkyl, —(C3-C20)-heteroaryl, —(
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: September 18, 2018
    Assignee: EVONIK DEGUSSA GMBH
    Inventors: Kaiwu Dong, Helfried Neumann, Ralf Jackstell, Matthias Beller, Robert Franke, Dieter Hess, Katrin Marie Dyballa, Dirk Fridag, Frank Geilen
  • Patent number: 10077233
    Abstract: The present disclosure concerns synthesis and anion binding features of poly-cyanostilbene macrocycles of Formula (I):
    Type: Grant
    Filed: July 10, 2017
    Date of Patent: September 18, 2018
    Assignee: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: Amar H. Flood, Semin Lee, Kevin McDonald